



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

AZD-5069

Cat. No.:	HY-19855
CAS No.:	878385-84-3
Molecular Formula:	C ₁₈ H ₂₂ F ₂ N ₄ O ₅ S ₂
Molecular Weight:	476.52
Target:	CXCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 90 mg/mL (188.87 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.0985 mL	10.4927 mL	20.9855 mL
	5 mM		0.4197 mL	2.0985 mL	4.1971 mL
	10 mM		0.2099 mL	1.0493 mL	2.0985 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 12.5 mg/mL (26.23 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
Solubility: 2.62 mg/mL (5.50 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for cancer treatment.

IC₅₀ & Target

¹²⁵I-IL-8-CXCR2

In Vitro

AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [125 I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GRO α -induced Ca $^{2+}$ flux in human neutrophils loaded with fluo-3 dye^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2022 Feb 16;13(1):890.
- J Extracell Vesicles. 2023 Jul;12(7):e12342.
- Cell Rep. 2023 Nov 13;42(11):113424.
- J Cereb Blood Flow Metab. 2023 May 17;271678X231175190.
- Cancers (Basel). 2023 Dec 1, 15(23), 5686.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Norman P, et al. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA